Eugia Pharma Specialities Limited Moxifloxacin Export Data — India (DGFT 2022–2026)

Name: Eugia Pharma Specialities Limited Moxifloxacin Export Records India — #3 Exporter, 39 Shipments, $1.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Moxifloxacin

India Pharmaceutical Trade Intelligence

$32.8M336 Suppliers137 CountriesHS 30049099

ExportsIndia → NIGERIA44.8%India → UNITED STATES17.5%

ImportsUNITED STATES → India$160.3B BRAZIL → India$30.7B

#1 Buyer: NATIONAL TUBERCULOSIS

Eugia Pharma Specialities Limited — Moxifloxacin Exporter #3 | $1.9M Trade Value | TransData Nexus | TransData Nexus

Eugia Pharma Specialities Limited — Moxifloxacin Exporter Profile

Indian Pharmaceutical Exporter · #3 for Moxifloxacin · $1.9M export value · DGFT Verified

Eugia Pharma Specialities Limited is the #3 Indian exporter of Moxifloxacin with $1.9M in export value and 39 verified shipments. Eugia Pharma Specialities Limited holds a 5.9% market share in Moxifloxacin exports across 1 countries. The company exports 49 pharmaceutical products worth $170.1M across 14 therapeutic categories.

Eugia Pharma Specialities Limited — Moxifloxacin Export Profile: Buyers & Destinations

Eugia Pharma Specialities Limited Moxifloxacin export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Moxifloxacin?

Country	Value	Shipments	Share
UNITED STATES	$5.8M	178	35.1%
NIGERIA	$2.8M	55	16.8%
NETHERLANDS	$1.7M	46	10.2%
THAILAND	$1.0M	38

Who Are the Top Buyers of Moxifloxacin from India?

Buyer	Country	Value	Orders
MYLAN INSTITUTIONAL INC 2898	UNITED STATES	$742.1K	16
AUROLOGISTICS LLC, (AUROBINDO PHARM	UNITED STATES	$650.0K	13
AUROBINDO PHARMA USA., INC,	UNITED STATES	$442.3K	9
TOPONE DISTRIBUTION LTD	CAMBODIA	$389.9K	14
I+SOLUTIONS	NETHERLANDS	$383.6K	9
J. KNIPPER & COMPANY	UNITED STATES	$381.1K	12
I+ SOLUTIONS,	NETHERLANDS	$350.0K	7
NORTHSTAR DISTRIBUTION CENTER 8912	UNITED STATES	$300.0K	6
MICRO NOVA PHARMACEUTICALS IND	NIGERIA	$300.0K	6
NATIONAL TUBERCULOSIS AND LEPROSY	NIGERIA	$100.0K	2

India's Moxifloxacin is purchased by 731 buyers worldwide. The top buyer is MYLAN INSTITUTIONAL INC 2898 (UNITED STATES), followed by AUROLOGISTICS LLC, (AUROBINDO PHARM and AUROBINDO PHARMA USA., INC,.

How Does Eugia Pharma Specialities Limited Compare to Nearest Moxifloxacin Exporters?

Exporters ranked immediately above and below #3 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
2	MSN LABORATORIES PRIVATE LIMITED	$2.3M	89	13	$25.9K
4	MICRO LABS LIMITED	$2.3M	86	14	$26.5K
3	EUGIA PHARMA SPECIALITIES LIMITED ★	$1.9M	39	1	$50.0K
5	AJANTA PHARMA LIMITED	$1.4M	112	11	$12.4K
1	MACLEODS PHARMACEUTICALS LTD	$1.4M	27	14	$50.0K

Eugia Pharma Specialities Limited ranks #3 among 336 Indian Moxifloxacin exporters. Average shipment value of $50.0K compared to the market average of $42.4K. The closest competitors by value are MSN LABORATORIES PRIVATE LIMITED and MICRO LABS LIMITED.

Which Indian Ports Ship Moxifloxacin Exports?

Port	Shipments	% Share
SAHAR AIR	311	12.9%
SAHAR AIR CARGO ACC (INBOM4)	263	10.9%
DELHI AIR CARGO ACC (INDEL4)	152	6.3%
DELHI AIR	132	5.5%
NHAVA SHEVA SEA (INNSA1)	126	5.2%
Bombay Air	119	4.9%
CHENNAI AIR	111	4.6%
CHENNAI AIR CARGO ACC (INMAA4)	93	3.9%

Geopolitical & Trade Policy Impact on Eugia Pharma Specialities Limited's Moxifloxacin Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Eugia. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased freight costs and extended transit times. These logistical hurdles are particularly impactful for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in supply chain management. (pharmaceuticalcommerce.com)

Conversely, U.S.-China trade tensions have opened avenues for Indian exporters. With the U.S. seeking to diversify its supply chains away from China, Indian pharmaceutical companies have the opportunity to capture a larger share of the U.S. market. Eugia's recent FDA approvals and product launches position it well to capitalize on this shift.

However, the imposition of new tariffs by the U.S. administration in August 2025, affecting over 60 countries including India, poses a significant challenge. These tariffs, reaching up to 39%, could impact nearly 55% of India's exports to the U.S., including pharmaceuticals. The increased cost burden may erode profit margins and affect competitiveness in the U.S. market. (apnews.com)

In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement. Indian exporters must ensure stringent adherence to serialization and traceability standards to maintain access to the EU market. Eugia's commitment to quality and regulatory compliance will be pivotal in navigating these regulatory landscapes.

Eugia Pharma Specialities Limited — Regulatory Compliance & Quality Standards

The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the USFDA intensifying inspections and compliance requirements. Eugia's experience with the USFDA's warning letter for its Unit-III facility underscores the importance of robust quality management systems. Addressing these regulatory observations is crucial for maintaining market access and reputation.

Indian pharmaceutical companies, including Eugia, are investing in upgrading manufacturing practices to meet international standards. This proactive approach is essential to mitigate risks associated with non-compliance and to sustain growth in regulated markets.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Moxifloxacin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Eugia Pharma Specialities Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 137+ countries, 731+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Moxifloxacin

Moxifloxacin

Eugia Pharma Specialities Limited — Moxifloxacin Exporter Profile

Eugia Pharma Specialities Limited — Moxifloxacin Export Profile: Buyers & Destinations

Where Does India Export Moxifloxacin?

Who Are the Top Buyers of Moxifloxacin from India?

What Is India's Total Moxifloxacin Export Value and How Much Does Eugia Pharma Specialities Limited Contribute?

What Is the Average Shipment Value for Eugia Pharma Specialities Limited's Moxifloxacin Exports?

How Does Eugia Pharma Specialities Limited Compare to Other Indian Moxifloxacin Exporters?

Regulatory Requirements: Exporting Moxifloxacin to Key Markets

United States — FDA

Nigeria — NAFDAC

How Does Eugia Pharma Specialities Limited Compare to Nearest Moxifloxacin Exporters?

Which Indian Ports Ship Moxifloxacin Exports?

What Other Advanced Antibiotics Products Does Eugia Pharma Specialities Limited Export?

Geopolitical & Trade Policy Impact on Eugia Pharma Specialities Limited's Moxifloxacin Exports

Eugia Pharma Specialities Limited — Regulatory Compliance & Quality Standards

About Eugia Pharma Specialities Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Moxifloxacin Export Data from Eugia Pharma Specialities Limited

Moxifloxacin Stats

Company Overview

Top Products by Eugia Pharma Specialities Limited

Related Analysis

Need Detailed Export Data?

Data Source